The effect of initial drug resistance on treatment response and acquired drug resistance during standardized short-course chemotherapy for tuberculosis

被引:70
作者
Seung, KJ
Gelmanova, IE
Peremitin, GG
Golubchikova, VT
Pavlova, VE
Sirotkina, OB
Yanova, GV
Strelis, AK
机构
[1] Partners Hlth, Boston, MA 02115 USA
[2] Partners Hlth, Moscow, Russia
[3] Tomsk Oblast Tuberculosis Serv, Tomsk, Russia
[4] Siberian State Med Univ, Tomsk, Russia
[5] Tomsk Oblast Tuberculosis Hosp, Tomsk, Russia
关键词
D O I
10.1086/425005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. In Tomsk Oblast, Russian Federation, during the period of 1996-2000, most previously untreated patients with tuberculosis received standardized short-course chemotherapy, irrespective of drug-susceptibility testing results. A retrospective analysis was done to determine the effect of initial drug resistance on treatment outcome and acquired drug resistance in new patients receiving standardized short-course chemotherapy. Methods. During the period of 1 November 1996 through 31 December 2000, a total of 2194 patients received a category 1 treatment regimen. Drug susceptibility test results for 1681 patients were available for analysis. Drug resistance patterns before and during treatment were compared for 73 patients whose culture results were persistently positive during treatment. Acquired resistance was defined as new drug resistance (during or at the end of treatment) that was not present at the beginning of treatment. Results. Pretreatment drug resistance was strongly associated with treatment failure. In patients who had strains with pretreatment resistance patterns that included isoniazid or rifampin resistance, but not resistance to both, 17 (70.8%) of 24 cases involving treatment failures acquired new multidrug resistance. In patients with pretreatment pan-susceptible or streptomycin-monoresistant strains, 13 (41.9%) of 31 cases involving treatment failures acquired new multidrug resistance. Conclusions. Early diagnosis of drug-resistant tuberculosis and judicious use of second-line drugs is recommended to decrease transmission of drug-resistant strains and to prevent the creation of multidrug-resistant strains. Finally, if drug susceptibility tests are not available or results are delayed, physicians should recognize that patients who do not respond to directly observed empirical short-course chemotherapy are at high risk of having multidrug- resistant tuberculosis and should be treated accordingly.
引用
收藏
页码:1321 / 1328
页数:8
相关论文
共 17 条
[1]   Incidence of multidrug-resistant tuberculosis in urban and rural India and implications for prevention [J].
Almeida, D ;
Rodrigues, C ;
Udwadia, ZF ;
Lalvani, A ;
Gothi, GD ;
Mehta, P ;
Mehta, A .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (12) :E152-E154
[2]  
[Anonymous], 2003, AM J RESP CRIT CARE, V167, P603
[3]  
CANETTI G, 1963, B WORLD HEALTH ORGAN, V29, P565
[4]   Standard short-course chemotherapy for drug-resistant tuberculosis -: Treatment outcomes in 6 countries [J].
Espinal, MA ;
Kim, SJ ;
Suarez, PG ;
Kam, KM ;
Khomenko, AG ;
Migliori, GB ;
Baéz, J ;
Kochi, A ;
Dye, C ;
Raviglione, MC .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (19) :2537-2545
[5]   Community based approaches to the control of multidrug resistant tuberculosis: introducing "DOTS-plus" [J].
Farmer, P ;
Kim, JY .
BRITISH MEDICAL JOURNAL, 1998, 317 (7159) :671-674
[6]  
Heifets LB, 1999, INT J TUBERC LUNG D, V3, P564
[7]   Recurrence in tuberculosis: relapse or reinfection? [J].
Lambert, ML ;
Hasker, E ;
Van Deun, A ;
Roberfroid, D ;
Boelaert, M ;
Van der Stuyft, P .
LANCET INFECTIOUS DISEASES, 2003, 3 (05) :282-287
[8]   Multicenter evaluation of ethambutol susceptibility testing of Mycobacterium tuberculosis by agar proportion and radiometric methods [J].
Madison, B ;
Robinson-Dunn, B ;
George, I ;
Gross, W ;
Lipman, H ;
Metchock, B ;
Sloutsky, A ;
Washabaugh, G ;
Mazurek, G ;
Ridderhof, J .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (11) :3976-3979
[9]   Comparison of the effectiveness of WHO short-course chemotherapy and standard Russian antituberculous regimens in Tomsk, western Siberia [J].
Mawer, C ;
Ignatenko, NV ;
Wares, DF ;
Strelis, AK ;
Golubchikova, VT ;
Yanova, GV ;
Lyagoshina, TV ;
Sharaburova, OE ;
Banatvala, N .
LANCET, 2001, 358 (9280) :445-449
[10]  
Migliori GB, 2002, INT J TUBERC LUNG D, V6, P858